737
(April 2021) Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way we live. As with all areas of life, drug consumption, related harms and drug markets have also been impacted, as have the services established to respond to drug-related problems. During the first weeks of the pandemic, the EMCDDA instigated two rapid assessment studies to identify the initial impact and implications of COVID-19.